By Staff Writer
Dr Mathias Mugoola has become very popular across Africa and the whole world of recent courtesy of his innovations and business entrepreneurship.
However, the founder of Dei Bio Pharma Africa’s best transformative $1.1 billion medical facility did not wake up to own the multibillion dollar business but endured from past experience to his success.
Dr Magoola has risen from malaria-stricken school boy to world acclaimed chemist pioneering Africa’s biggest Dei Bio pharmaceutical firm driving the continent’s most ambitious scientific undertakings.
“This is not just a factory. It’s a launchpad for an African revolution in medicine,” Dr Mathias Magoola humbly says.
“We are building Africa’s pharmaceutical future. Our goal is to provide high-quality, affordable medicine across therapeutic areas that affect billions.” Magoola stressed.
Magoola’s life has been shaped by adversity. Raised in poverty, he accessed university through a state scholarship and studied chemistry while battling recurrent malaria. His recovery was aided by a local herbal for malaria yet free of the side effects. That experience ignited his curiosity, leading to his first international patent and a lifelong commitment to pharmaceutical innovation.
Today, he has submitted over 100 patent applications with the United States Patent and Trademark Office (USPTO), spanning treatments for cancer, Alzheimer’s, HIV, diabetes, and other critical diseases.
Dei BioPharma has already absorbed over $700 million in construction, technology, and Research &Development. Built to meet global standards, the complex features 12 production lines that will manufacture a wide range of therapies—from generic antibiotics and insulin to MRNA vaccines, monoclonal antibodies, and cancer immunotherapies.
The GMP certification ensures operations meet rigorous benchmarks set by regulators. While final product approvals by the U.S. FDA and World Health Organization (WHO) are pending, the milestone marks a pivotal move toward pharmaceutical sovereignty—for Uganda, and potentially all of Africa.
At the core of Dei BioPharma’s innovation pipeline are several disruptive technologies. One standout is a guided RNA-based cancer therapy, engineered to selectively destroy mutated cancer cells while sparing healthy tissue—promising safer and dramatically cheaper alternatives to chemotherapy and radiation.
There’s a huge opportunity here to democratize cancer care,” “We can treat all types of cancer, at any stage, and reduce the cost from thousands of dollars to under $100.” Joly Magoola says
He has also innovated a universal vaccine for Foot and Mouth Disease (FMD)—a major threat to African livestock economies. Patented in early 2025, the vaccine offers cross-strain protection and could save Uganda billions in animal health and vaccine imports.
According to Magoola Dei BioPharma is also pushing boundaries in neuroscience with experimental Alzheimer’s therapies designed to cross the blood-brain barrier, one of medicine’s most difficult frontiers.
With patents secured and clinical protocols filed, trials for the company’s cancer and Alzheimer’s therapies are expected to begin before the end of 2025. Emergency use authorizations are under review. Meanwhile, its mRNA COVID-19 vaccine—stored in U.S. cell banks—is designed for rapid updating in response to emerging variants.
Though firmly rooted in Uganda, Dei BioPharma operates through global partnerships with technology leaders including Shimadzu (Japan), Agilent Technologies (USA), Cytiva (UK), FabTech (UAE), and United Pharmatek (USA). Their equipment and expertise have enabled the facility to meet stringent international standards.
Mainly because of the IP in its innovations, Dei Biopharma is now valued in excess of $3 Billion. The $1.1 capital investment is financed through a blend of shareholder equity, commercial loans, and government backing. A crucial $100 million credit line from Equity Bank Uganda helped jump start construction, while the Ugandan government now holds a 9.4% equity stake.
His other innovations in Uganda
Dei Group recently unveiled Organic One fertilizer in Uganda market which will be used to boost food production.
The same company launched Bella wheat flour for nutrition enhancement among other range of products.
Magoola attributes his success to presidential political support from Kenya’s President William Ruto and President Yoweri Museveni.
Magoola focus is to make life-saving treatments accessible to all.
He also envisions a system focused on access and equity to African-made medicine for the world’s underserved.
“Over six billion people can’t afford the cost of biological drugs. A treatment for acute kidney failure currently costs $3,000. We can deliver it for under $100.”
Magoola’s future plans
Dei BioPharma is preparing for its next chapter—scaling operations and expanding talent. Already Uganda’s largest private R&D employer, the company plans to create 40,000 high-income jobs.
The Matugga facility will also become a continental export hub, with capacity to produce over one billion doses of MRNA vaccines annually. It is on track to become one of the most important pharmaceutical centers in the Global South.
Dei BioPharma recently crossed a critical threshold. Uganda’s National Drug Authority (NDA) granted Good Manufacturing Practices (GMP) certification to two of the facility’s twelve planned production lines, clearing the way for commercial manufacture of capsules and tablets by mid-2025.
